As an example of a combinatory trial, there is a phase 1b/2 clinical trial using chemotherapy in the presence with both Everolimus with Lapatinib (a dual tyrosine kinase inhibitor that inhibits both HER2 and EGF receptors) to treat metastatic HER-2 positive breast cancer (ClinicalTrials.gov Identifier: NCT01783756). This evidence concerns the gene ERBB2 and breast carcinoma.